Efbemalenograstim Alfa Side Effects
Medically reviewed by Drugs.com. Last updated on Sep 10, 2024.
Applies to efbemalenograstim alfa: parenteral injection for sub-q use.
Side effects include:
Adverse effects reported in ≥10% of patients receiving efbemelanograstim alfa-vuxw include nausea, anemia, and thrombocytopenia.
For healthcare professionals
Applies to efbemalenograstim alfa: subcutaneous solution.
General adverse events
The most common adverse reactions with a frequency of 10% or greater were nausea, anemia, thrombocytopenia, fatigue, and bone pain.[Ref]
Cardiovascular
- Frequency not reported: Capillary leak syndrome, aortitis
Hematologic
- Very common (10% or more): Anemia (up to 12%), thrombocytopenia (up to 10%)
- Frequency not reported: Sickle cell crisis, leukocytosis
Hypersensitivity
- Frequency not reported: Serious allergic reactions
Oncologic
- Frequency not reported: Myelodysplastic syndrome, acute myeloid leukemia
Other
- Frequency not reported: Splenic rupture
Respiratory
- Frequency not reported: Acute respiratory distress syndrome
Genitourinary
- Very common (10% or more): Nausea (up to 42%)
Renal
- Frequency not reported: Glomerulonephritis
References
1. (2023) "Product Information. Ryzneuta (efbemalenograstim alfa)." Evive Biotech
More about efbemalenograstim alfa
- efbemalenograstim alfa consumer information
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: colony stimulating factors
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Efbemalenograstim alfa side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.
